Shares of MorphoSys AG (ETR:MOR – Get Rating) have received an average recommendation of “N/A” from the seven ratings firms that are presently covering the company, MarketBeat reports. The average 12-month price target among brokers that have issued ratings on the stock in the last year is €55.14 ($59.94).
A number of research firms have recently commented on MOR. Deutsche Bank Aktiengesellschaft set a €30.00 ($32.61) target price on MorphoSys in a research report on Tuesday, March 22nd. Berenberg Bank set a €65.00 ($70.65) target price on MorphoSys in a research report on Thursday, March 24th. Barclays set a €36.00 ($39.13) target price on MorphoSys in a research report on Thursday, March 17th. Finally, JPMorgan Chase & Co. set a €40.00 ($43.48) target price on MorphoSys in a research report on Thursday, March 17th.
ETR MOR traded down €0.91 ($0.99) during trading on Thursday, reaching €24.76 ($26.91). 188,580 shares of the company’s stock were exchanged, compared to its average volume of 153,687. The company has a 50 day moving average price of €24.96 and a two-hundred day moving average price of €31.99. The company has a debt-to-equity ratio of 133.04, a quick ratio of 3.79 and a current ratio of 3.98. MorphoSys has a 1 year low of €20.76 ($22.57) and a 1 year high of €80.14 ($87.11). The stock has a market cap of $845.52 million and a P/E ratio of -1.61.
MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia.
- Insiders Are Selling Palo Alto Networks
- Greenbrier Companies Stock has Green in its Future
- Tilray Stock Has Better Days Ahead
- Headwinds Mount For Carmax, Don’t Count On Higher Share Prices
- 3 Bank Stocks That Are Ready to Handle Whatever the Fed Throws at Them
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.